Zhengyun Zou

ORCID

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 14

Top Venues

Epigenomics

Journal of translational medicine

Journal for immunotherapy of cancer

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Lianjun Zhao, Yu Ren, Guiying Zhang, Kelin Zheng, Jiayu Wang, Huizi Sha, Mengke Zhao, Rong Huang, Donglin Kang, Xinyu Su, Yirong Wu, Wangling Zhang, Ruihe Lai, Lin Li, Rui Mei, Yitao Wang, You Tian, Fufeng Wang, Baorui Liu, Zhengyun Zou
Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma. Journal for immunotherapy of cancer 12 (6) (2024)
Lianjun Zhao, Yu Ren, Guiying Zhang, Kelin Zheng, Jiayu Wang, Huizi Sha, Mengke Zhao, Rong Huang, Donglin Kang, Xinyu Su, Yirong Wu, Wangling Zhang, Ruihe Lai, Lin Li, Rui Mei, Yitao Wang, You Tian, Fufeng Wang, Baorui Liu, Zhengyun Zou
Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma. Journal for immunotherapy of cancer 12 (6) (2024)
Lianjun Zhao, Yu Ren, Guiying Zhang, Kelin Zheng, Jiayu Wang, Huizi Sha, Mengke Zhao, Rong Huang, Donglin Kang, Xinyu Su, Yirong Wu, Wangling Zhang, Ruihe Lai, Lin Li, Rui Mei, Yitao Wang, You Tian, Fufeng Wang, Baorui Liu, Zhengyun Zou
Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma. Journal for immunotherapy of cancer 12 (6) (2024)
Rong Huang, Mengke Zhao, Guiying Zhang, Yueling Yang, Jiayu Wang, Kelin Zheng, Lin Li, Xinyu Su, Lianjun Zhao, Yirong Wu, Zhengyun Zou
Trauma plays an important role in acral melanoma: A retrospective study of 303 patients. Cancer medicine 13 (7) (2024)
Rong Huang, Mengke Zhao, Guiying Zhang, Yueling Yang, Jiayu Wang, Kelin Zheng, Lin Li, Xinyu Su, Lianjun Zhao, Yirong Wu, Zhengyun Zou
Trauma plays an important role in acral melanoma: A retrospective study of 303 patients. Cancer medicine 13 (7) (2024)
Lianjun Zhao, Yu Ren, Guiying Zhang, Kelin Zheng, Jiayu Wang, Huizi Sha, Mengke Zhao, Rong Huang, Donglin Kang, Xinyu Su, Yirong Wu, Wangling Zhang, Ruihe Lai, Lin Li, Rui Mei, Yitao Wang, You Tian, Fufeng Wang, Baorui Liu, Zhengyun Zou
Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma. Journal for immunotherapy of cancer 12 (6) (2024)
Rong Huang, Gaigai Shen, Yu Ren, Kelin Zheng, Jiayu Wang, Yan Shi, Jiani C Yin, Lanqun Qin, Guiying Zhang, Mengke Zhao, Xinyu Su, Luqiao Li, Fufeng Wang, Yang Shao, Baorui Liu, Zhengyun Zou
Prognostic value of genetic aberrations and tumor immune microenvironment in primary acral melanoma. Journal of translational medicine 21 (1) (2023)
Rong Huang, Gaigai Shen, Yu Ren, Kelin Zheng, Jiayu Wang, Yan Shi, Jiani C Yin, Lanqun Qin, Guiying Zhang, Mengke Zhao, Xinyu Su, Luqiao Li, Fufeng Wang, Yang Shao, Baorui Liu, Zhengyun Zou
Prognostic value of genetic aberrations and tumor immune microenvironment in primary acral melanoma. Journal of translational medicine 21 (1) (2023)
Rong Huang, Yirong Wu, Zhengyun Zou
Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects. Epigenomics 14 (22) (2023)
Rong Huang, Gaigai Shen, Yu Ren, Kelin Zheng, Jiayu Wang, Yan Shi, Jiani C Yin, Lanqun Qin, Guiying Zhang, Mengke Zhao, Xinyu Su, Luqiao Li, Fufeng Wang, Yang Shao, Baorui Liu, Zhengyun Zou
Prognostic value of genetic aberrations and tumor immune microenvironment in primary acral melanoma. Journal of translational medicine 21 (1) (2023)
Rong Huang, Yirong Wu, Zhengyun Zou
Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects. Epigenomics 14 (22) (2023)
Rong Huang, Gaigai Shen, Yu Ren, Kelin Zheng, Jiayu Wang, Yan Shi, Jiani C Yin, Lanqun Qin, Guiying Zhang, Mengke Zhao, Xinyu Su, Luqiao Li, Fufeng Wang, Yang Shao, Baorui Liu, Zhengyun Zou
Prognostic value of genetic aberrations and tumor immune microenvironment in primary acral melanoma. Journal of translational medicine 21 (1) (2023)
Rong Huang, Yirong Wu, Zhengyun Zou
Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects. Epigenomics 14 (22) (2023)
Rong Huang, Yirong Wu, Zhengyun Zou
Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects. Epigenomics (2023)

Zhengyun Zou.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Zhengyun Zou